Bipolar Disorder Market was valued around USD 0.49 billion in 2018 and is estimated to grow at a CAGR of 1.66% to reach USD 0.53 billion by 2023.
Bipolar depression is a mental disorder whose symptoms include periods with mood swings of severe depression or emotional highs. It was once called Manic Depression. In recent years, the general public awareness on the symptoms and treatment of Bipolar Disorder is on the rise. Typically, the treatment for bipolar disorder is for lifetime.
Bipolar disorder market is growing at a slow yet constant pace. Advancements in technology allowing the detection of a patient’s mood with more accuracy act as a positive influence on the market growth. Government’s Bipolar Disorder awareness campaigns also propel the market growth.
The key restraints on the market growth come from the inadequate facilities for diagnosis of bipolar disorder. Strict government rules on misdiagnosis of the disorder and insufficient equipment result in bipolar disorder being written off as just another personality disorder or depression. Several of the drugs used in treatment of the disorder have been found to have addictive side-effects, resulting in a controlled manufacturing of the required pharmaceuticals.
The market is segmented by type, by Mechanism of Action and by Drug Class. By type the market is classified as Bipolar I disorder, Bipolar II disorder and Cyclothymic disorder. Under Mechanism of Action, the market is segmented into Monoamine oxidase inhibitors, Tricyclic antidepressants, Benzodiazepines, Serotonin-norepinephrine reuptake inhibitors, Beta blockers, Selective serotonin reuptake inhibitors and others. This market segment is predicted to be led by Serotonin-norepinephrine reuptake inhibitors till 2018 owing to their safety in treating major depression. The market is classified by Drug Class into Antianxiety drugs, Mood stabilizers, Antidepressant drugs, Antipsychotic drugs, Anticonvulsants. Rising occurrence of depression stemming from physical illness and psychosis resulted in Antipsychotic drugs leading this market segment.
By geography the market is segmented into China, India, Korea, Japan, and others. The increasing awareness about bipolar disorder and the developing healthcare infrastructure in the rapidly developing countries of the region such as India and China are expected to be the major drivers of the region.
Lead players in the market are Gedeon Richter, Indivior, AstraZeneca, Janssen Pharmaceuticals, Lundbeck, Bristol-Myers Squibb, Ostuca Holdings Co. Ltd., Glaxo SmithKline (GSK), Allergan Plc, Pfizer, Inc and AbbVie, Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Method
5.1.1 Introduction
5.1.2 Genotypic
5.1.3 Proteomics-based
5.1.4 Phenotypic
5.1.5 Y-o-Y Growth Analysis, By Method
5.1.6 Market Attractiveness Analysis, By Method
5.1.7 Market Share Analysis, By Method
5.2 Application
5.2.1 Introduction
5.2.2 F&B
5.2.3 Diagnostic
5.2.4 Pharmaceutical
5.2.5 Environmental
5.2.6 Y-o-Y Growth Analysis, By Application
5.2.7 Market Attractiveness Analysis, By Application
5.2.8 Market Share Analysis, By Application
5.3 Product
5.3.1 Introduction
5.3.2 Identification Services
5.3.3 Consumables
5.3.4 Instruments
5.3.5 Y-o-Y Growth Analysis, By Products and Services
5.3.6 Market Attractiveness Analysis, By Products and Services
5.3.7 Market Share Analysis, By Products and Services
5.4 End User
5.4.1 Food Manufacturing Industries
5.4.2 Pharmaceutical Companies
5.4.3 Hospitals and Diagnostic Centres
5.4.4 Other End users
5.3.5 Y-o-Y Growth Analysis, By End User
5.3.6 Market Attractiveness Analysis, By End User
5.3.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Method
6.1.3.3 By Application
6.1.3.4 By Product
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Method
6.1.4.3 By Application
6.1.4.4 By Product
6.1.4.5 By End user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Method
6.1.5.3 By Application
6.1.5.4 By Product
6.1.5.5 By End user
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Shimadzu Corporation
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Dickinson & Company
8.3 Biolog Inc.
8.4 Merck KGaA
8.5 IEH Laboratories & Consulting Group
8.6 Trivitron Healthcare
8.7 Laboratory Corporation of America Holdings
8.8 Thermo Fisher Scientific Inc.
8.9 Bruker Corporation
8.10 Charles River Laboratories
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
